Jupiter Orphan Therapeutics Inc., of Jupiter, Fla., submitted an IND to the FDA for Jotrol as a treatment for mucopolysaccharidosis type I (MPS I). After a pharmacokinetics trial, Jupiter plans to test Jotrol, a trans-resveratrol product, in patients with Friedreich's ataxia, MPS I and potentially other mitochondrial dysfunction related diseases. Read More
Tenax Therapeutics Inc., of Morrisville, N.C., said it has regained compliance with the minimum bid price requirement of $1 per share for continued listing on Nasdaq. To accomplish that, the company completed a 1-for-20 reverse stock split of its outstanding common stock. Read More
On Target Laboratories Inc., of West Lafayette, Ind. a privately held biotech developing tumor-targeted fluorescent dyes to improve cancer surgery, has secured $11.1 million in additional financing as part of its series B round, which initially closed in September 2017, led by Johnson & Johnson Innovation's JJDC Inc. Read More
AMSTERDAM – Europe's famously fragmented system – or systems – for pricing and reimbursement will lose a few rough edges in the years ahead, as coordinated clinical assessment of product dossiers becomes the norm for all therapeutic products that are currently subject to the EMA's centralized market authorization process. Read More
AMSTERDAM - The journey for JAK1 tyrosine kinase inhibitor filgotinib has been a bumpy one, advancing among three partners in a dozen years, to find its current place in phase III development for rheumatoid arthritis (RA), Crohn's disease and other autoimmune indications. Read More
Romidepsin, a histone deacetylase (HDAC) inhibitor and FDA-approved lymphoma drug, reversed the social deficits of autism spectrum disorder (ASD) in a mouse model of the condition. Read More
AMSTERDAM - A new report published Wednesday by the European Investment Bank (EIB), titled "Financing the next wave of medical breakthroughs – What works and what needs fixing," found that lack of funding limits the growth of the European life sciences industry, particularly companies working in research and development. Read More
Foghorn Therapeutics Inc., a Cambridge, Mass.-based startup devoted to developing new cancer drugs that exploit the chromatin regulatory system to direct gene expression, has launched with an initial capital commitment of $50 million from Flagship Pioneering, the 17-year-old venture firm previously known as Flagship Ventures. Read More
